PMC:7228307 / 1447-1669 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":146,"end":152},"obj":"Chemical"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:D011134"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor s"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":156,"end":163},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor s"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T16","span":{"begin":0,"end":2},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T17","span":{"begin":3,"end":5},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T18","span":{"begin":138,"end":145},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T19","span":{"begin":183,"end":185},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor s"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":156,"end":163},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor s"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T2","span":{"begin":156,"end":163},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor s"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"25","span":{"begin":146,"end":152},"obj":"Chemical"}],"attributes":[{"id":"A25","pred":"pubann:denotes","subj":"25","obj":"MESH:D011134"}],"text":"FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor s"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T8","span":{"begin":156,"end":163},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor s"}